By mid-April 2024, India-based Biocon Biologics signed an exclusive licensing and supply agreement that will allow Brazil’s Biomm SA to commercialise semaglutide, which is used to control type-2 diabetes in adults and has been repurposed for obesity management.
Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil
Home/Pharma News
|
Posted 12/06/2024
0
Post your comment
![Diabetes V14K06 Diabetes V14K06](/var/gabi/storage/images/media/images/diabetes-v14k06/24897-1-eng-GB/Diabetes-V14K06_large.jpg)
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight loss.
Novo Nordisk’s Ozempic, Rybelsus, and Wegovy were approved in Europe in 2017, 2020, and 2021, respectively. Ozempic, a formulation of semaglutid, is expected to go off-patent by 2026 in various markets.
Under the terms of this agreement, Biocon will develop, manufacture and supply the drug product, while Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.
Biomm focuses on developing, manufacturing and commercializing complex biotech and biosimilar drug products at its production facility in Nova Lima.
According to the Diabetes Atlas of the International Diabetes Federation (IDF), Brazil ranks fifth in the world for the highest incidence of diabetes, with 16.8 million adults aged 20 to 79 years old affected by the disease, and an estimated 21.5 million cases by 2030. The total addressable market for Semaglutide in Brazil stands at around US$580 million, based on IQVIA Moving Annual Total 2023 data.
New drugs have the largest share of the pharmaceutical market in Brazil, while biological drugs are the ones that have grown the most [1].
The Brazilian pharmaceutical market is the third largest in the Americas region, after Canada and the US, and it ranks first in the Latin American region [2].
Related articles
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Fiocruz and Pfizer sign agreement for generic of Xeljanz
LATIN AMERICAN FORUM View the latest headline article: Actualización de los biosimilares aprobados por Health Canada en 2023 Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: Actualización de los biosimilares aprobados por Health Canada en 2023 !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
References
1. GaBI Online - Generics and Biosimilars Initiative. Pharmaceutical manufacturing companies in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 12]. Available from:
www.gabionline.net/generics/general/pharmaceutical-manufacturing-companies-in-brazil
2. GaBI Online - Generics and Biosimilars Initiative. The pharmaceutical market in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 12]. Available from: www.gabionline.net/generics/general/The-pharmaceutical-market-in-Brazil
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.
Policies & Legislation
China’s NMPA expands global ties with Netherlands and Indonesia
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus
Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements
Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab
Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM
Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus
![Application V15a16 Application V15a16](/var/gabi/storage/images/media/images/application-v15a16/25577-1-eng-GB/Application-V15a16_large.jpg)
Home/Pharma News Posted 16/07/2024
Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements
![Shaking hands V13D29 Shaking hands V13D29](/var/gabi/storage/images/media/images/shaking-hands-v13d294/22672-1-eng-GB/Shaking-hands-V13D29_large.jpg)
Home/Pharma News Posted 05/06/2024
Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab
![Turkey 2016 COVER V16E31DG Turkey 2016 COVER V16E31DG](/var/gabi/storage/images/media/images/turkey-2016-cover-v16e31dg/51945-1-eng-GB/Turkey-2016-COVER-V16E31DG_large.jpg)
Home/Pharma News Posted 28/05/2024
Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM
![02 AA010638 02 AA010638](/var/gabi/storage/images/media/images/02-aa010638/21726-1-eng-GB/02-AA010638_large.jpg)
Home/Pharma News Posted 14/05/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment